Sigyn Therapeutics, Inc.

Equities

SIGY

US82674U2050

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 17:27:32 15/05/2024 BST			5-day change	1st Jan Change
5.25 ^USD	+5.00%		-.--%	+10.99%

05-14	Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-20	Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 31, 2023 at 11:14 am

Sigyn Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 2.93 million compared to USD 3 million a year ago. Basic loss per share from continuing operations was USD 3.2 compared to USD 3.2 a year ago.

Diluted loss per share from continuing operations was USD 3.2 compared to USD 3.2 a year ago.

Latest news about Sigyn Therapeutics, Inc.

Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-20	CI
Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer	12-12	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Sigyn Therapeutics, Inc. Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application	17/05/23	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Sigyn Therapeutics, Inc. Announces Appointment of Annette Marleau as Chief Scientific Officer	11/04/23	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Sigyn Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Sigyn Therapeutics, Inc. Announces Cancer-Related Patent Submission	06/10/22	CI
Sigyn Therapeutics, Inc. Announces Board Changes, Effective October 10, 2022	04/10/22	CI
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients	14/09/22	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Sigyn Therapeutics, Inc. has filed an IPO in the amount of $9.2 million.	22/06/22	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board	26/04/22	CI
Sigyn Therapeutics, Inc. Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board	31/03/22	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	21/03/22	CI
Sigyn Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	20/03/22	CI
Sigyn Therapeutics, Inc. Appoints H. David Humes, MD to Its Scientific Advisory Board	15/03/22	CI
Sigyn Therapeutics, Inc. Appoints Alexander S. Yevzlin to its Scientific Advisory Board	09/03/22	CI
Sigyn Therapeutics, Inc. Appoints Jeremy Ferrell as Chief Financial Officer, Effective March 9, 2022	02/03/22	CI
Sigyn Therapeutics Announces Completion of Animal Studies	23/02/22	CI

Chart Sigyn Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sigyn Therapeutics, Inc. (Sigyn) is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Companyâs development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SIGYN THERAPEUTICS, INC.	+10.99%	6.61M
ABBOTT LABORATORIES	-6.24%	180B
MEDTRONIC PLC	-6.39%	98.89B
BECTON, DICKINSON AND COMPANY	-5.97%	66.26B
DEXCOM, INC.	-9.61%	44.61B
CENCORA, INC.	+8.84%	44.02B
HOYA CORPORATION	+10.13%	40.12B
METTLER-TOLEDO INTERNATIONAL, INC.	+12.69%	29.19B
TERUMO CORPORATION	+13.33%	23.41B
WEST PHARMACEUTICAL SERVICES, INC.	-7.83%	23.64B

Other Medical Equipment, Supplies & Distribution